Parametric Portfolio Associates’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Parametric Portfolio Associates’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-21,410	Closed	-$142K	–	4044
2019 Q2	$142K	Buy	+21,410	New	+$81.5K	﹤0.01%	3804
2018 Q4	–	Sell	-5,513	Closed	-$109K	–	4011
2018 Q3	$109K	Buy	5,513 +2,412	+78%	+$61K	﹤0.01%	3838
2018 Q2	$98K	Buy	3,101 +1,091	+54%	+$39.3K	﹤0.01%	3812
2018 Q1	$74K	Sell	2,010 -118	-6%	-$7.76K	﹤0.01%	3881
2017 Q4	$168K	Buy	+2,128	New	+$157K	﹤0.01%	3780

Other funds holding MLNT

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Parametric Portfolio Associates's MLNT Position: Q3 2019 in Review

Parametric Portfolio Associates sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q3 2019, closing a stake of 21,410 shares — an estimated $142K sold.

Parametric Portfolio Associates first reported a position in MLNT in Q4 2017 and held it in 5 quarters. The position peaked at $168K in Q4 2017. 47 funds tracked by Wall St. Rank hold MLNT as of Q3 2019.

Parametric Portfolio Associates reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Parametric Portfolio Associates sold 21,410 Melinta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $142K.
Parametric Portfolio Associates first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 5 quarters.
Parametric Portfolio Associates's Melinta Therapeutics, Inc. Common Stock position peaked at $168K in Q4 2017.
47 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Parametric Portfolio Associates's 13F filing for Q3 2019, filed 15 Nov 2019.